Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 5Recruiting 3Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 6Lung Neoplasms 6Prostatic Neoplasms 5Breast Neoplasms 5Multiple Myeloma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Osteosarcoma 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Barrett Esophagus 3Wilms Tumor 2Urinary Bladder Neoplasms 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Biphenotypic, Acute 2Gastroesophageal Reflux 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Adenocarcinoma Of Esophagus 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urethral Neoplasms 1

Interventions

Gemcitabine 9Cisplatin 5vinflunine 4Carboplatin 4pembrolizumab 2enfortumab vedotin 2Ramucirumab 2Platinum 2Docetaxel 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1genexol-PM 1eribulin 1enzalutamide 1dehydroftorafur 1carotuximab 1avelumab 1atezolizumab 1abexinostat 1Vitamin D 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide 1Molecular Diagnostic Techniques 1Mitozytrex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ureteral Neoplasms × Specimen Handling × Clear all
NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡